3rd Anti-Infectives Partnering & Deal-Making Summit
http://gtcbio.com/confpage.asp?cid=11
January 26-27, 2006
The San Diego Marriott La Jolla, CA

Dear Colleague,

GTCbio's 3rd Annual Anti-infectives Partnering and Deal-making Summit (January 26-27, 2006 at the The San Diego Marriott La Jolla, CA) is approaching quickly. If you haven’t already registered for this meeting, please do so early.

Register by Monday, December 26, 2005 to receive 10% early bird discount. You can register o­nline at www.gtcbio.com, call 626-256-6405 or fax your registration to 626-256-6460.

The 3rd annual Anti-Infectives Partnering & Deal-Making Summit will provide a unique venue where o­ne can learn about the anti-infective business development trends, the infectious disease markets, and the novel technologies that shape up the industry. The conference will include panel discussions o­n Investment Opportunities, The recent Partnerships in Infectious Diseases, and the Bird Flu Pandemic. This conference will provide an excellent forum for partnering and collaborating by bringing together conceptual innovators from all active parties working in Infectious diseases, including researchers, business development representatives, Venture Capitalists, regulators, and entrepreneurs.

Keynote Speaker:
Ken Collins, President and CEO, Replidyne
“From a Biotech to a Biopharmaceutical Company: The Replidyne Story”

CONFIRMED Speakers:

David Pompliano, Ph.D., Vice President & Head of Biology, GlaxoSmithKline
Sundeep Lal, Ph.D., MBA, Senior Director, External Scientific Affairs, Merck & Co.
Yujiro Hata, MBA, Senior Vice President, Business Development, Enanta Pharmaceuticals

Mark Afenito, Ph.D., President, Kalobios
Ken Collins, President & CEO, Replydine, Inc.
David Apelian, Chief Scientific Officer, GlobeImmune

Kevin Eastwood, VP, Business Development, Achillion Pharmaceuticals
Lisa Haile, Ph.D., J.D., Partner, DLA Piper Rudnick Gray Cary
Volker Janssen, Ph.D., Partner, Simon-Kucher & Partners

Eckard Weber, M.D., Venture Partner, Domain Associates
Camille Samuels, Managing Director, Versant Ventures
Jeanne Cunicelli, Partner, Bay City Capital

Kevin Judice, Ph.D., Chief Scientific Officer, Achaogen, Inc.
Graham Johnson, Chief Research Officer, Rib-X Pharmaceuticals
Clement Lewin, VP, US Gov Affairs & Strategy, Acambis

Tom Kassberg, SVP, Business Development & Corporate Strategy, Intermune Pharmaceuticals
John Lebbos, M.D., Principal Director, Infectious Diseases and Immune & Inflammatory Disease, Decision Resources, Inc.
Michael McCully, Director, Recombinant Capital

Dennis Molnar, Exec Dir, Corp Development, Paratek Pharmaceuticals
Paul D. Olivo, M.D., Ph.D., President & CSO, Apath, LLC
Elaine Cheung, Sr Mgr Business Development, VaxGen

Douglas F. Wall, Principal & Managing Director, West Coast, Venture Advisors
Jeff Stein, Partner, San Diego, Sofinnova Ventures
Henrik Stender, Ph.D., Vice President, Research & Development, AdvanDx

Katherine Taylor, Ph.D., Therapeutics Development Program Officer, Office of Biodefense Res Affairs , DMID, NIAID, NIH
Elizabeth Posillico, Ph.D., President & CEO, Elusys Therapeutics
Glenn S. Tillotson, Ph.D., FRSM, Vice President, Scientific and Medical Relations, Oscient Pharmaceuticals

Praveen Tipirneni, Senior Director, Corporate Development, Cubist Pharmaceuticals
Mang Yu, Ph.D., President & CEO, NexBio, Inc.
Victoria Gordon, Managing Director, EcoBiotics
Ursula Theuretzbacher, Ph.D., Founder, Center for Anti-Infective Agents

Please bring this conference to the attention of your colleagues who may benefit from attending. Please register early and submit an abstract.

ABSTRACT SUBMISSION DEADLINE*: December 26, 2005

*A few abstracts will be selected for oral presentation. To submit an abstract visit www.gtcbio.com/abstract.asp

Early Registration Deadline: November 26, 2005

For a detailed agenda please visit www.gtcbio.com